Biomea Fusion Inc (BMEA)

$1.81 -0.11 (-5.73%)
Market Cap 114.26M
Revenue (ttm) 0.00
Net Income (ttm) -138.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 636,500
Avg Vol 922,970
Day's Range N/A - N/A
Shares Out 59.51M
Stochastic %K 10%
Beta -0.13
Analysts Strong Sell
Price Target $7.62

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle con...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 980 9099
Address:
1599 Industrial Road, San Carlos, United States
Rob88ynn
Rob88ynn Sep. 9 at 3:00 PM
$BMEA 1.80 is where it wants to be
0 · Reply
Patoun
Patoun Sep. 9 at 1:53 PM
$BMEA on the contrary, I think they chose not participating to this event simply because they will, as expected, announce the official data soon through a press release. Releasing early information during this event would potentially create insider trading conflicting situations.
1 · Reply
GODOFUSD
GODOFUSD Sep. 9 at 10:42 AM
$BMEA ok... no EADS 2025 to go suck dicks because money run away. I hope they come back somme with a big deal because this news is a red flag
1 · Reply
GODOFUSD
GODOFUSD Sep. 8 at 8:16 PM
$BMEA
0 · Reply
hashbridges
hashbridges Sep. 8 at 5:10 PM
$BMEA algos back in control until news. Don't want this getting back to $2.
0 · Reply
GODOFUSD
GODOFUSD Sep. 5 at 8:13 PM
$BMEA watching all those biotech pumping +100-1000% this month... BMEA should be next
1 · Reply
GODOFUSD
GODOFUSD Sep. 5 at 4:19 PM
$BMEA 17 octobre 2025 : 83 puts, 2 245 calls 16 janvier 2026 : 174 puts, 1 479 calls market bet upside move
0 · Reply
raulsan79trader
raulsan79trader Sep. 5 at 4:00 PM
$BMEA Bullish cross of moving averages 20 & 50 ⬆️
0 · Reply
GODOFUSD
GODOFUSD Sep. 5 at 3:16 PM
$BMEA 1.8 is the pivot level. If price remain above 1.5, 6$ is next
0 · Reply
Patoun
Patoun Sep. 5 at 2:02 PM
$BMEA
1 · Reply
Latest News on BMEA
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 5, 2025, 4:05 PM EDT - 4 weeks ago

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Jul 24, 2025, 7:00 AM EDT - 6 weeks ago

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 23, 2025, 7:00 AM EDT - 2 months ago

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Jun 18, 2025, 7:00 AM EDT - 2 months ago

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Jun 18, 2025, 6:28 AM EDT - 2 months ago

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Biomea Fusion Announces Pricing of Public Offering of Securities

Jun 17, 2025, 11:15 PM EDT - 2 months ago

Biomea Fusion Announces Pricing of Public Offering of Securities

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Jun 17, 2025, 7:28 PM EDT - 2 months ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR

Biomea Fusion Announces Proposed Public Offering of Securities

Jun 17, 2025, 4:33 PM EDT - 2 months ago

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

Jun 13, 2025, 6:45 AM EDT - 3 months ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 14, 2025, 4:05 PM EDT - 4 months ago

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

May 5, 2025, 4:05 PM EDT - 4 months ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2025, 4:01 PM EDT - 5 months ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 31, 2025, 4:10 PM EDT - 5 months ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 5 months ago

Biomea Fusion Announces Leadership Transition

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Mar 24, 2025, 8:30 AM EDT - 6 months ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2025, 8:00 AM EST - 6 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Feb 27, 2025, 8:00 AM EST - 6 months ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Dec 17, 2024, 10:41 AM EST - 9 months ago

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 17, 2024, 8:10 AM EST - 9 months ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 16, 2024, 6:15 PM EST - 9 months ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 12, 2024, 5:02 PM EST - 9 months ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Dec 9, 2024, 4:01 PM EST - 9 months ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Dec 6, 2024, 8:00 AM EST - 9 months ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Nov 3, 2024, 11:00 AM EST - 11 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 11 months ago

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Oct 30, 2024, 4:00 PM EDT - 11 months ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 29, 2024, 4:46 PM EDT - 11 months ago

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 11 months ago

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Oct 28, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 26, 2024, 11:00 AM EDT - 11 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

Oct 22, 2024, 11:00 AM EDT - 11 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Oct 21, 2024, 9:00 AM EDT - 11 months ago

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 20, 2024, 11:00 AM EDT - 11 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 19, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Oct 18, 2024, 11:00 AM EDT - 11 months ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 17, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Oct 15, 2024, 4:05 PM EDT - 11 months ago

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Should Contact The Schall Law Firm

Oct 8, 2024, 11:00 AM EDT - 1 year ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Should Contact The Schall Law Firm

Rob88ynn
Rob88ynn Sep. 9 at 3:00 PM
$BMEA 1.80 is where it wants to be
0 · Reply
Patoun
Patoun Sep. 9 at 1:53 PM
$BMEA on the contrary, I think they chose not participating to this event simply because they will, as expected, announce the official data soon through a press release. Releasing early information during this event would potentially create insider trading conflicting situations.
1 · Reply
GODOFUSD
GODOFUSD Sep. 9 at 10:42 AM
$BMEA ok... no EADS 2025 to go suck dicks because money run away. I hope they come back somme with a big deal because this news is a red flag
1 · Reply
GODOFUSD
GODOFUSD Sep. 8 at 8:16 PM
$BMEA
0 · Reply
hashbridges
hashbridges Sep. 8 at 5:10 PM
$BMEA algos back in control until news. Don't want this getting back to $2.
0 · Reply
GODOFUSD
GODOFUSD Sep. 5 at 8:13 PM
$BMEA watching all those biotech pumping +100-1000% this month... BMEA should be next
1 · Reply
GODOFUSD
GODOFUSD Sep. 5 at 4:19 PM
$BMEA 17 octobre 2025 : 83 puts, 2 245 calls 16 janvier 2026 : 174 puts, 1 479 calls market bet upside move
0 · Reply
raulsan79trader
raulsan79trader Sep. 5 at 4:00 PM
$BMEA Bullish cross of moving averages 20 & 50 ⬆️
0 · Reply
GODOFUSD
GODOFUSD Sep. 5 at 3:16 PM
$BMEA 1.8 is the pivot level. If price remain above 1.5, 6$ is next
0 · Reply
Patoun
Patoun Sep. 5 at 2:02 PM
$BMEA
1 · Reply
GODOFUSD
GODOFUSD Sep. 5 at 1:08 PM
$BMEA FDA focuses on diabetes and obesity. Let's see if biomea react to this news https://fr.tradingview.com/news/reuters.com,2025:newsml_L8N3US0R8:0/
0 · Reply
GODOFUSD
GODOFUSD Sep. 5 at 12:56 PM
$BMEA
0 · Reply
GODOFUSD
GODOFUSD Sep. 4 at 9:02 PM
$BMEA here is what I think. Hold that level and up to 2.17-2.37 or back in the green box to form an inverted head and shoulder. Since April 1.8 acted like a magnet 🧲 zone. So, is it the moment where it turn into support or another shake out to make ppl upset and sell ? What I'm sure is that another dip will let me add more. Since April my plan remains the same: buy below 1.8!
0 · Reply
GODOFUSD
GODOFUSD Sep. 4 at 7:06 PM
$BMEA
0 · Reply
GODOFUSD
GODOFUSD Sep. 4 at 6:49 PM
$BMEA see you
0 · Reply
GODOFUSD
GODOFUSD Sep. 4 at 6:14 PM
$BMEA the last bears will start to freak if 1.8 HOLD
0 · Reply
GODOFUSD
GODOFUSD Sep. 4 at 5:56 PM
$BMEA interesting
0 · Reply
GODOFUSD
GODOFUSD Sep. 4 at 2:59 PM
$BMEA very often price jump arroud a level of support/resistance before conforming the next trend. since april we are testing 1.8 will it turn support ? it's very likely because we see a growing interest below that level with increasing volumes and institutionals buy and hedge funds closing shorts we have 2 possibilities: we continue to jump around and go back again in those green box, OR this time we confirm a clear 1.8 support and start an uptrend I don't think that since april we are forming a distribution channel to go lower. the clear signal will be once 2.03 turn support!
0 · Reply
GODOFUSD
GODOFUSD Sep. 4 at 2:31 PM
$BMEA since April, 1.8 acted as a magnet zone. buying below 1.8 was the winning deal. Hold that level or back down again! Up trend will start once 2.03 finally turn support!
0 · Reply
Patoun
Patoun Sep. 4 at 2:13 PM
$BMEA I do not want to hurt anyone here, but some people speaks too much, several messages per day... When will you understand that other people are monitoring conversation on markets forums (volume of messages, content etc) to then push to suppress the dtock price... Believe me, if they do not see any conversation activity, they will panic, not knowing in what direction to go. Please be quiet. Like with the secret service, the less you say the better it is. PLEASE !!!
1 · Reply
GODOFUSD
GODOFUSD Sep. 4 at 1:51 PM
$BMEA daily close above 1.91 or i expect an inverted head and shoulder. Seem that we are back testing the magnet zone (1.8)
0 · Reply
Rob88ynn
Rob88ynn Sep. 4 at 1:49 PM
$BMEA falling hard
0 · Reply